basal cell carcinoma. Malignant neoplasm of skin, unspecified
Conditions
Interventions
The treatment involves subcutaneous administration of three million unite interferon alpha 2b ampule at a dose of 0.15 cubic centimeters per lesion three times a week for three successive weeks..
Treatment - Drugs
The treatment involves subcutaneous administration of three million unite interferon alpha 2b ampule at a dose of 0.15 cubic centimeters per lesion three times a week for three successive weeks.
Sponsors
Vice-chancellery for Research and Technology, Mashhad University of Medicla Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Informed written consent for participation; definitive diagnosis of basal cell carcinoma of skin in pathology; and age 18 years old or above. Exclusion criteria: Morphea-like basal cell carcinoma of skin; nodulo-ulcerative basal cell carcinoma; pregnancy and breast-feeding; previous history of severe complications with interferon alpha 2b; no intent to complete the treatment course; no intent to complete the follow-up period; previous history of cardiovascular disease; previous history of thromboembolic disease; local radiotherapy on the target region; previous history of arsenic exposure; and immune insufficiency.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response. Timepoint: Every two months. Method of measurement: Physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Neutropenia. Timepoint: on a weekly basis. Method of measurement: Complete blood count.;Headache. Timepoint: on a weekly basis. Method of measurement: Medical history.;Fatigue. Timepoint: on a weekly basis. Method of measurement: Medical history.;Pathologic response. Timepoint: Two months after completion of treatment. Method of measurement: Biopsy.;Fever. Timepoint: on a weekly basis. Method of measurement: Physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mehdi Razmara Farzaghi
Mashhad University of Medical Sciences
Outcome results
None listed